Mancuso, K.; Barbato, S.; Di Raimondo, F.; Gay, F.; Musto, P.; Offidani, M.; Petrucci, M.T.; Zamagni, E.; Zambello, R.; Cavo, M.
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168.
https://doi.org/10.3390/cancers17071168
AMA Style
Mancuso K, Barbato S, Di Raimondo F, Gay F, Musto P, Offidani M, Petrucci MT, Zamagni E, Zambello R, Cavo M.
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers. 2025; 17(7):1168.
https://doi.org/10.3390/cancers17071168
Chicago/Turabian Style
Mancuso, Katia, Simona Barbato, Francesco Di Raimondo, Francesca Gay, Pellegrino Musto, Massimo Offidani, Maria Teresa Petrucci, Elena Zamagni, Renato Zambello, and Michele Cavo.
2025. "Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma" Cancers 17, no. 7: 1168.
https://doi.org/10.3390/cancers17071168
APA Style
Mancuso, K., Barbato, S., Di Raimondo, F., Gay, F., Musto, P., Offidani, M., Petrucci, M. T., Zamagni, E., Zambello, R., & Cavo, M.
(2025). Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers, 17(7), 1168.
https://doi.org/10.3390/cancers17071168
